human interleukin-12 Fc fusion protein

Human interleukin-12 Fc fusion protein is a recombinant cytokine therapy designed to enhance the pharmacokinetic profile of interleukin-12 (IL-12) for cancer immunotherapy. IL-12 is a proinflammatory cytokine that activates natural killer (NK) cells and T cells, promoting interferon-gamma (IFNγ) secretion and T helper 1 (Th1) polarization. While wild-type IL-12 Fc fusions (hIL-12-Fc) extend the short serum half-life of recombinant IL-12, they are often associated with severe dose-limiting toxicities, such as systemic cytokine spikes and liver enzyme elevations, primarily driven by acute NK cell activation. To improve the therapeutic window, engineered variants like **STK-026** have been developed as partial agonists with reduced affinity for the IL-12Rβ1 subunit. These engineered proteins aim to avoid the initial burst of NK cell activation while maintaining sustained stimulation of antigen-experienced T cells and NK cells within the tumor microenvironment, potentially allowing for improved tolerability and anti-tumor efficacy in advanced solid malignancies.

Other names

human IL-12-FcIL-12-Fc fusion proteinIL12-Fc fusion proteinIL 12-Fc fusion protein